REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2012

Mar 21, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-03-15

Reporting Person: GOLDSTEIN JOSEPH L (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-03-15	Common Stock	M	4600	$18.61	Acquired	4600	Direct
2012-03-15	Common Stock	S	4600	$110.77	Disposed	0	Direct
2012-03-15	Common Stock	M	400	$18.61	Acquired	400	Direct
2012-03-15	Common Stock	S	400	$111.06	Disposed	0	Direct
2012-03-15	Common Stock	M	5000	$18.61	Acquired	5000	Direct
2012-03-15	Common Stock	S	5000	$115	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-03-15	Non-Qualified Stock Option (right to buy)	$18.61	M	4600	Disposed	2019-01-02	Common Stock (4600)	Direct
2012-03-15	Non-Qualified Stock Option (right to buy)	$18.61	M	400	Disposed	2019-01-02	Common Stock (400)	Direct
2012-03-15	Non-Qualified Stock Option (right to buy)	$18.61	M	5000	Disposed	2019-01-02	Common Stock (5000)	Direct

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: Represents volume-weighted average price of sales of 4,600 shares of Company stock on March 15, 2012 at prices ranging from $110.01 to $110.99.. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 15, 2012 at each separate price.

F3: Represents volume-weighted average price of sales of 400 shares of Company stock on March 15, 2012 at prices ranging from $111.00 to $111.10.. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 15, 2012 at each separate price.

F4: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant

F5: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.